Biogen loses its R&D chief to a small biotech
This article was originally published in Scrip
Douglas Williams, who has been Biogen's executive vice president of R&D since January 2011, is leaving the company to become CEO of an as-yet unnamed biotechnology start-up. He will be the first member of a new organization with potential in cancer diagnostics and therapy, according to Biogen. Responsibility for Biogen's R&D will be assumed by Alfred Sandrock, chief medical officer, and Spyros Artavanis-Tsakonas, chief scientific officer. "While I am sad to leave Biogen I am excited about the opportunity to follow a real passion of mine," said Dr Williams. There has been a spate of recent high-profile departures from pharma companies to head up small biotechs.